
Differing apixaban dosing recommendations for atrial fibrillation patients with kidney disease, as outlined by the US FDA and European Medicines Agency, have sparked debate. An electronic health record data study from 2013 to 2021 examined patients with atrial fibrillation and severe kidney disease (stage 4/5) initiating apixaban. Results indicated that the 5 mg dose was linked to a higher risk of bleeding compared to the 2.5 mg dose, aligning with European Medicines Agency guidance. However, there was no significant difference in the risk of stroke/systemic embolism or death, emphasizing the importance of kidney function-based dosing recommendations.
Like
Save
Share